Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
153 enrolled
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
335 enrolled
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2 Recruiting
2,000 enrolled
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
147 enrolled
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
93 enrolled
ACCELERATE
Phase 2 Recruiting
358 enrolled
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
25 enrolled
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
Phase 2 Recruiting
35 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 Recruiting
31 enrolled
VEN-R DASA
Phase 2 Recruiting
35 enrolled
STOP VEN
Phase 2 Recruiting
50 enrolled
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
120 enrolled
Ivosidenib as Post-HSCT Maintenance for AML
Phase 2 Recruiting
75 enrolled
TRILLIUM
Phase 2 Recruiting
83 enrolled
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Phase 2 Recruiting
45 enrolled
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Phase 2 Recruiting
50 enrolled
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Phase 2 Recruiting
28 enrolled
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Phase 2 Recruiting
56 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 Recruiting
37 enrolled
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Phase 2 Recruiting
36 enrolled
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Phase 2 Recruiting
30 enrolled
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 Recruiting
63 enrolled
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
160 enrolled
CHANCE
Phase 2 Recruiting
25 enrolled
GANCE
Phase 2 Recruiting
25 enrolled
FLUCLORIC
Phase 2 Recruiting
302 enrolled
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Phase 2 Recruiting
20 enrolled
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Phase 2 Recruiting
36 enrolled
TAGALONG
Phase 2 Recruiting
53 enrolled
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase 2 Recruiting
102 enrolled
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Phase 2 Recruiting
91 enrolled 26 charts
CAV Regimen for R/R AML
Phase 2 Recruiting
68 enrolled
CM-AML-001
Phase 2 Recruiting
134 enrolled
Cladribine Venetoclax in Monocytic AML
Phase 2 Recruiting
20 enrolled
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Phase 2 Recruiting
130 enrolled
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Phase 2 Recruiting
15 enrolled
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Recruiting
30 enrolled
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Phase 2 Recruiting
100 enrolled
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2 Recruiting
240 enrolled
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Phase 2 Recruiting
172 enrolled
RAFA
Phase 2 Recruiting
70 enrolled
Personalized NK Cell Therapy in CBT
Phase 2 Recruiting
100 enrolled
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Phase 2 Recruiting
40 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Phase 2 Recruiting
140 enrolled
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2 Recruiting
45 enrolled
VERDI
Phase 2 Recruiting
29 enrolled